Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Abstract Pluripotent stem cells (PSCs) hold great potential for novel therapeutic approaches to regenerate or replace functionally impaired tissues. Since the introduction of the induced pluripotent stem cell technology in 2006, the number of scientific publications on this topic has constantly been increasing. However, so far no therapy based on PSCs has found its way into routine clinical use. In this study, we examined research trends related to clinical trials involving PSCs based on data obtained from ClinicalTrials.gov, the ICTRP database from the World Health Organization, as well as from a search of all individual databases that are included in the ICTRP using a multistep search algorithm. Following a stringent inclusion/exclusion procedure 131 studies remained that could be classified as clinical trials involving PSCs. The magnitude of these studies (77.1%) was observational, which implies that no cells were transplanted into patients, and only a minority of studies (22.9%) were of an interventional study type. The number of clinical trials involving induced pluripotent stem cells (iPSCs, 74.8%) was substantially higher than the one involving embryonic stem cells (ESCs, 25.2%). However, the picture changes completely when focusing on interventional studies, where in the majority (73.3%) of cases ESCs were used. Interestingly, also the study duration was significantly shorter for interventional versus observational trials (p = 0.002). When focusing on the geographical study regions, it became obvious that the greatest part of all observational trials was performed in the USA (41.6%) and in France (16.8%), while the magnitude of interventional studies was performed in Asian countries (China 36.7%, Japan 13.3%, South Korea 10.0%) and in the field of ophthalmology. In summary, these results indicate that only a limited number of trials were focusing on the actual transplantation of PSCs into patients in a rather narrow field of diagnoses. The future will tell us, if the iPSC technology will ultimately overcome the current challenges and will finally make its way into routine clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although both methods have low reprogramming efficiency, Sendai virus-mediated reprogramming has been used for several clinical applications, notably, in cystic fibrosis, the AIDS vaccine, and other iPSC replacement therapies [29,30,31,32,33].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [30]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Nature Reviews Molecular Cell Biology
(2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/41580.1471-0080 · Cited by 2,565
Philosophical Transactions of the Royal Society of London (A)
(1889) · Rendiconti del Circolo Matematico di Palermo · doi:10.1007/bf03017132 · Cited by 2,245
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Advances in Experimental Medicine and Biology
Lunt, G. G. (1986) · Neurochemistry International · doi:10.1016/0197-0186(86)90020-3 · Cited by 1,851
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509
Immunogenicity of induced pluripotent stem cells
Zhao, T., Zhang, Z.-N., Rong, Z., & Xu, Y. (2011) · Nature · doi:10.1038/nature10135 · Cited by 1,444
Embryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409
Research works printed but not linked: 2
- Stoddard-Bennett T Reijo Pera R Treatment of Parkinson’s disease through personalized medicine and induced pluripotent stem cells Cells 2019 8 26 PMC6357081 30621042 · DOI · Paper page
- Regulation of stem cell research in Europe. Vol. 2020 (ed. Mahalatchimy, A.) (https://www.eurostemcell.org).
Cited by
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
A Brief Overview of Global Trends in MSC-Based Cell Therapy
Jovic, D., Yu, Y., Wang, D., Wang, K., Li, H., Xu, F., Liu, C., Liu, J., & Luo, Y. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10369-1 · Cited by 286
“Most of the studies performed in China are interventional which indicates that use of the MSCs cells in clinical practice is larger than the other cell products such as iPSCs which had far fewer clinical studies and were mostly observational [115].”
Aboul-Soud, M. A. M., Alzahrani, A. J., & Mahmoud, A. (2021) · Cells · doi:10.3390/cells10092319 · Cited by 204
Applications of synthetic biology in medical and pharmaceutical fields
Yan, X., Liu, X., Zhao, C., & Chen, G.-Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01440-5 · Cited by 179
Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells
Kim, J. Y., Nam, Y., Rim, Y. A., & Ju, J. H. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10262-3 · Cited by 148
Metadata
- Authors
- Deinsberger, J., Reisinger, D., & Weber, B.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Weber, Benedikt
- Venue
- npj Regenerative Medicine
- Published
- 2020-09-11
- Volume
- 5
- Issue
- 1
- Pages
- 15-15
- ISSN
- 2057-3995 (ISSN-L)
- PMC
- PMC7486930
- OpenAlex
- W3045676218
- Cited by
- 158
- References
- 63
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 30 · 2020: 2
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Regenerative Medicine (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Vienna Science and Technology Fund (LS18-080)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- pluripotent stem cells, induced pluripotent stem cells, embryonic stem cells, clinical trials, research trends, stem cell transplantation, International Clinical Trials Registry Platform, ClinicalTrials.gov, ophthalmology, regenerative medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. https://app.cochat.ai/papers/10.1038/s41536-020-00100-4
- The paper
- Deinsberger, J., Reisinger, D., & Weber, B. (2020). Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. npj Regenerative Medicine. https://doi.org/10.1038/s41536-020-00100-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.